Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis

Richeldi, Luca; M. du Bois, Roland; Raghu, Ganesh; Azuma, Arata; M. Brown, Kevin; Costabel, Ulrich; Cottin, Vincent; R. Flaherty, Kevin; M. Hansell, David; Inoue, Yoshikazu; Soon Kim, Dong; Kolb, Martin; G. Nicholson, Andrew; W. Noble, Paul; Selman, Moisés; Taniguchi, Hiroyuki; Brun, Michèle; Le Maulf, Florence; Girard, M; Stowasser, Susanne; Schlenker‐Herceg, Rozsa; Disse, Bernd; R. Collard, Harold

doi:10.1056/nejmoa1402584

Public

Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis

Published in New England Journal of Medicine • May 18, 2014

Authors:

Luca Richeldi

Roland M. du Bois

Ganesh Raghu

Abstract

BACKGROUND: Nintedanib (formerly known as BIBF 1120) is an intracellular inhibitor that targets multiple tyrosine kinases. A phase 2 trial suggested that treatment with 150 mg of nintedanib twice daily reduced lung-function decline and acute exacerbations in patients with idiopathic pulmonary fibros...

Subject

Nintedanib

Medicine

Idiopathic pulmonary fibrosis

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!